Cardiac risk in the treatment of breast cancer: assessment and management
Antonis Valachis,1 Cecilia Nilsson2 1Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; 2Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden Abstract: As the number of long-term breast cancer survivors has in...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ab8433f1ba2449d19c6062e18f76802a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Antonis Valachis,1 Cecilia Nilsson2 1Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; 2Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden Abstract: As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities. Keywords: adjuvant, anthracyclines, cardiac toxicity, radiotherapy, trastuzumab |
|---|